CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79.75% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Netherlands' Redcare Pharmacy slightly beats Q3 revenue estimates on strong prescription sales in Germany

By Reuters News


Overview

  • Netherlands online pharmacy's Q3 revenue grew 18% yr/yr, slightly beating analyst expectations

  • Adjusted EBITDA margin rose 1.0pp to 3.4%, with adjusted EBITDA up 68% yr/yr

  • Growth driven by strong prescription sales in Germany and expanding customer base


Outlook

  • Redcare Pharmacy sees 2026 revenue growth of 16% to 18%

  • Company expects 2026 non-Rx revenue growth of 10% to 12%

  • Redcare Pharmacy forecasts 2026 Rx revenue in Germany at EUR 730 mln to EUR 760 mln


Result Drivers

  • GERMAN RX SALES - Company said strong prescription sales in Germany drove revenue growth

  • CUSTOMER BASE EXPANSION - Co attributed growth to increase in active customer base

  • LOWER MARKETING SPEND - Co said improved profitability was partly due to reduced marketing expenses and lower cost per order


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

Slight Beat*

EUR 847 mln

EUR 843.97 mln (3 Analysts)

Q3 Net Income

EUR 1 mln

*Applies to a deviation of less than 1%; not applicable for per-share numbers.


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 3 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the drug retailers peer group is "buy"

  • Wall Street's median 12-month price target for Redcare Pharmacy NV is €96.00, about 21.1% above its October 28 closing price of €79.25

  • The stock recently traded at 90 times the next 12-month earnings vs. a P/E of 274 three months ago


Reuters Recommended Reads

  • Oct 28 - Unilever tops Q3 sales estimates, raises dividend

  • Oct 27 - UK's Reckitt Q3 like-for-like revenue rises 3.2% on Emerging Markets growth

  • Oct 27 - Dutch regulator blocks takeover of Unilever's Unox brand


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.